



**BANGKOK
HOSPITAL**
HEADQUARTER

**ANNUAL TUMOR
REGISTRY 2021**



Message from **DIRECTOR**

| | |
|--|----|
| Message from Director | 5 |
| Tumor Registry 2021 : Team | 6 |
| Cancer Registry 2021 : Abstract | 7 |
| Annual Cancer Registry 2021 | 8 |
| <i>Distribution of All Cancer by Age and Gender, The Top 10 Leading Site of Cancer, Patient Category of All Cancer, Method of Diagnosis, Staging, Primary Treatment, Patient Follow up, Patient Nationality, The Top 10 Leading Site of Thai Patient Cancer, The Top 10 Leading Site of Non-Thai Patient Cancer</i> | |
| Review of Breast Cancer | 27 |
| Review of Lung Cancer | 33 |
| Review of Colorectal Cancer | 38 |
| Review of Prostate Cancer | 44 |
| Review of Thyroid Cancer | 49 |
| Hematologic Malignancies 2021 | 54 |
| Age Distribution in All Male Cancer Number of Case | 70 |
| Age Distribution in All Female Cancer Number of Case | 72 |

Message from **DIRECTOR**

Dear all:

The COVID-19 pandemic continues to evolve, as does our response. The devastating impact of the COVID-19 pandemic coincided with a long overdue on cancer patients and healthcare provider. It has challenged us, made us adapt to new realities and stimulated us to never give up. But most importantly, it has made us proud of what The Bangkok Cancer Hospital Wattanosoth and Bangkok Hospital Headquarter can achieve together in a time of great crisis.

Like most all businesses, the unprecedented coronavirus pandemic has had a ripple effect on healthcare sectors. One of the major challenges we saw early on and throughout the crisis, was the adverse impact on our client organizations and more specifically our local. However, despite facing the wrath of the pandemic, we showed continued resilience and initiative. We are committed to respecting different comfort levels and making service for our cancer patients, as well as hospital support, as safe as possible.

The importance and increased focus on diversity in the hospital has peaked over the course of the past few years. And the urgency of objectives is more pronounced than ever. As we move forward in 2022 and beyond, we will see organizations continue to place an emphasis on their cancer service through strategic, unique plans that are designed for lasting sustainability.



With gratitude,
Thiravud Khuhaprema, M.D., FRCST., FICS., Visiting Professor
Hospital Director,
Bangkok Cancer Hospital Wattanosoth



Tumor Registry 2021 :

TEAM

Dr.Thiravud
Khuhaprema

Consultant

Dr.Parsert
Lertsanguansinchai

Consultant

Clin. Prof. Dr.Sudsawat
Laohavinij

Consultant

Dr.Komgrit
Tanisaro

Consultant

Dr.Pongtorn
Kietdumrongwong

Consultant

Dr.Pravich
Tanyasittisuntorn

Consultant

Dr.Surachai
Sitawarin

Chairperson

Dr.Chompunut
Wongprasert

Vice Chairperson

Dr.Natthaphum
Kanchanaporn

Committee

Dr.Darin
Jaturapatporn

Committee

Dr.Photsawee
Khemapipat

Committee

Khun Paranee
Pongnoppakun

Committee

Khun Warut
Chaiwong

Committee

Khun Waraphorn
Chomphu

Secretary

Khun Kritwaroj
Patchetphokin

Ass.Secretary

Tumor Registry 2021 :

ABSTRACT

The total of new cases diagnosed as malignancy at Bangkok Hospital Headquarter (BHQ) is 2,242 cases (Solid tumor is 2,096 cases and Hematologic malignant is 146 cases). There was significantly increased (31%) in the total number as compared to 1,547 cases in 2020.

The gender ratio is 1:1 This age distribution has not changed since the year 2020. Patients who are between 40-74 y/o are the majority accounting for more than half of all. The average age in male patients is 50-74 y/o. which is slightly older than the female age of 40-64 y/o.

Top 5 malignancies are:

- | | |
|---|----------------------------|
| 1) Breast (Included DCIS) - 27.03 percent | 4) Prostate - 7.27 percent |
| 2) Lung - 11.42 percent | 5) Thyroid - 7.00 percent |
| 3) Colorectal - 9.50 percent | |

The trend for top 5 malignancies has not changed over the past 11 years (2006-2020). For the past 10 years, the top 5 have been: Breast, Lung, Colorectal Liver & Hepatobiliary and Prostate. However, when compared to last year, the overall number of cases in Breast cancer increased significantly by 35.81 percent, Lung cancer increased by 26.56 percent, Colorectal cancer increased by 34.27 percent, Prostate cancer increased by 30.67 percent and Thyroid cancer increased by 27.39 percent.

The results of overall staging of patients who received treatment at Bangkok Hospital Headquarter (BHQ) are: Stage 0 is 2.79 percent, Stage I is 22.67 percent, Stage II is 20.75 percent, Stage III is 24.59 percent, and Stage IV is 21.13 percent. Unspecified stage (due to lack of pertinent information) is 6.34 percent. And in cases of Brain cancer has no stage grouping applies in AJCC Staging manual is 1.73 percent. All results are similar to 2020 staging results.

Analysis of the primary treatment modalities indicates that Radiation therapy continues to be the majority (54.37 percent), followed by Surgery (31.41 percent), Chemotherapy (4.80 percent), and Radioactive Iodine Therapy (RAI) (5.76 percent) and Concurrent chemoradiation (2.02) percent.

Patients who are still living after diagnosis or receiving treatment in 2021 is 97.19 percent and patients who died with cancer as the cause are 2.81 percent. At this time no patients receiving treatment have been lost to follow-up.

Ratio of Thai to non-Thai patients is 1:1 in year 2021 equal to the year 2020. The top 5 rankings of non-Thai patients are: Myanmar, Cambodian, Bangladeshi, American and British respectively.

The Top 5 malignancies of Thai patients are:

- | | |
|---|----------------------------|
| 1) Breast (Included DCIS) - 32.88 percent | 4) Thyroid - 7.56 percent |
| 2) Lung - 12.60 percent | 5) Prostate - 5.94 percent |
| 3) Colorectal - 9.88 percent | |


The Top 5 malignancies of non-Thai patients are:

- | | |
|---|-------------------------------|
| 1) Breast (Included DCIS) - 17.70 percent | 4) Colorectal - 10.95 percent |
| 2) Prostate g - 12.96 percent | 5) Thyroid - 7.30 percent |
| 3) Lung - 11.13 percent | |

BANGKOK HOSPITAL HEADQUARTER ANNUAL CANCER REGISTRY 2021

ALL NEW CANCER CASE IN BANGKOK HOSPITAL HEADQUARTER 2006 - 2021

All Patient




THE TOP 10 LEADING SITE OF NEW CANCER PATIENTS BY GENDER


| Code | Primary site | Male | | Female | | Total | |
|----------|-------------------------|--------|---------|--------|---------|--------|---------|
| | | Number | Percent | Number | Percent | Number | Percent |
| C50, D05 | Breast (included DCIS) | 7 | 0.74 | 599 | 46.11 | 606 | 27.03 |
| C33-C34 | Lung | 150 | 15.91 | 106 | 8.16 | 256 | 11.42 |
| C18-C20 | Colorectal | 128 | 13.57 | 85 | 6.54 | 213 | 9.50 |
| C61 | Prostate | 163 | 17.29 | 0 | 0.00 | 163 | 7.27 |
| C73 | Thyroid gland | 45 | 4.77 | 112 | 8.62 | 157 | 7.00 |
| C00-C14 | Head & Neck | 80 | 9.49 | 31 | 2.39 | 111 | 4.95 |
| C22-C24 | Liver and Hepatobiliary | 69 | 7.32 | 28 | 2.16 | 97 | 4.33 |
| C81-C88 | Lymphoma | 53 | 5.62 | 42 | 3.23 | 95 | 4.24 |
| C53 | Cervix | 0 | 0.00 | 93 | 7.16 | 93 | 4.15 |
| C54 | Endometrium | 0 | 0.00 | 65 | 5.00 | 65 | 2.90 |

THE TOP 10 LEADING SITE OF NEW CANCER PATIENTS BY GENDER

All Patient




2020




THE TOP 10 LEADING SITE OF NEW CANCER PATIENTS IN MALE

Male




THE TOP 10 LEADING SITE OF NEW CANCER PATIENTS IN FEMALE

FEMALE



DISTRIBUTION OF NEW ALL CANCER PATIENTS BY AGE GROUP AND GENDER (ALL PATIENTS)


| Age | Male | | Female | | Total | |
|--------------|------------|---------------|--------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 3 | 0.32 | 4 | 0.31 | 7 | 0.31 |
| 20 - 24 | 3 | 0.32 | 7 | 0.54 | 10 | 0.45 |
| 25 - 29 | 12 | 1.27 | 31 | 2.39 | 43 | 1.92 |
| 30 - 34 | 17 | 1.80 | 69 | 5.31 | 86 | 3.84 |
| 35 - 39 | 37 | 3.92 | 96 | 7.39 | 133 | 5.93 |
| 40 - 44 | 61 | 6.47 | 142 | 10.93 | 203 | 9.05 |
| 45 - 49 | 49 | 5.20 | 155 | 11.93 | 204 | 9.10 |
| 50 - 54 | 97 | 10.29 | 191 | 14.70 | 288 | 12.85 |
| 55 - 59 | 109 | 11.56 | 179 | 13.78 | 288 | 12.85 |
| 60 - 64 | 120 | 12.73 | 137 | 10.55 | 257 | 11.46 |
| 65 - 69 | 170 | 18.03 | 108 | 8.31 | 278 | 12.40 |
| 70 - 74 | 123 | 13.04 | 72 | 5.54 | 195 | 8.70 |
| 75 - 79 | 82 | 8.70 | 58 | 4.46 | 140 | 6.24 |
| 80 - 84 | 34 | 3.61 | 21 | 1.62 | 55 | 2.45 |
| 85 - 89 | 22 | 2.33 | 15 | 1.15 | 37 | 1.65 |
| 90 - 94 | 3 | 0.32 | 11 | 0.85 | 14 | 0.62 |
| 95 + | 1 | 0.11 | 3 | 0.23 | 4 | 0.18 |
| Total | 943 | 100.00 | 1,299 | 100.00 | 2,242 | 100.00 |




PATIENT CATEGORY OF NEW ALL CANCER PATIENTS IN BANGKOK HOSPITAL HEADQUARTER (ALL PATIENTS)

| Patient treatment | Male | | Female | | Total | |
|-----------------------|------------|---------------|--------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Treatment in BHQ | 411 | 43.58 | 690 | 53.12 | 1101 | 49.11 |
| Treatment outside BHQ | 532 | 56.42 | 609 | 46.88 | 1141 | 50.89 |
| Total | 943 | 100.00 | 1,299 | 100.00 | 2,242 | 100.00 |

All Patient




DISTRIBUTION OF NEW ALL CANCER PATIENTS BY TYPE OF DIAGNOSIS (ALL PATIENT)




DISTRIBUTION OF NEW ALL CANCER PATIENTS BY AGE GROUP AND GENDER (SOLID TUMOR)

| Age | Male | | Female | | Total | |
|--------------|------------|---------------|--------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 3 | 0.35 | 3 | 0.24 | 6 | 0.29 |
| 20 - 24 | 3 | 0.35 | 5 | 0.40 | 8 | 0.38 |
| 25 - 29 | 8 | 0.93 | 21 | 1.70 | 29 | 1.38 |
| 30 - 34 | 13 | 1.51 | 65 | 5.25 | 78 | 3.72 |
| 35 - 39 | 35 | 4.07 | 92 | 7.44 | 127 | 6.06 |
| 40 - 44 | 50 | 5.82 | 140 | 11.32 | 190 | 9.06 |
| 45 - 49 | 45 | 5.24 | 146 | 11.80 | 191 | 9.11 |
| 50 - 54 | 91 | 10.59 | 187 | 15.12 | 278 | 13.26 |
| 55 - 59 | 103 | 11.99 | 174 | 14.07 | 277 | 13.22 |
| 60 - 64 | 110 | 12.81 | 130 | 10.51 | 240 | 11.45 |
| 65 - 69 | 157 | 18.28 | 102 | 8.25 | 259 | 12.36 |
| 70 - 74 | 116 | 13.50 | 68 | 5.50 | 184 | 8.78 |
| 75 - 79 | 71 | 8.27 | 57 | 4.61 | 128 | 6.11 |
| 80 - 84 | 31 | 3.61 | 20 | 1.62 | 51 | 2.43 |
| 85 - 89 | 19 | 2.21 | 13 | 1.05 | 32 | 1.53 |
| 90 - 94 | 3 | 0.35 | 11 | 0.89 | 14 | 0.67 |
| 95 + | 1 | 0.12 | 3 | 0.24 | 4 | 0.19 |
| Total | 859 | 100.00 | 1,237 | 100.00 | 2,096 | 100.00 |




PATIENT CATEGORY OF NEW ALL CANCER PATIENTS IN BANGKOK HOSPITAL HEADQUARTER (SOLID TUMOR)

| Patient treatment | Male | | Female | | Total | |
|-----------------------|------------|---------------|--------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Treatment in BHQ | 375 | 43.66 | 666 | 53.84 | 1041 | 49.67 |
| Treatment outside BHQ | 484 | 56.34 | 571 | 46.16 | 1055 | 50.33 |
| Total | 859 | 100.00 | 1,237 | 100.00 | 2,096 | 100.00 |




DISTRIBUTION OF NEW ALL CANCER PATIENTS BY TYPE OF DIAGNOSIS (SOLID TUMOR)




DISTRIBUTION OF NEW ALL CANCER PATIENTS BY STAGING (SOLID TUMOR)
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


All Gender



Male



Female



Stage 0 = Carcinoma in situ

Non stage = In case of Brain tumor

Unspecified stage = Incomplete staging due to insufficient patient information

DISTRIBUTION OF NEW ALL CANCER PATIENTS BY TREATMENT (SOLID TUMOR)

| Type of treatment | Male | | Female | | Total | |
|--------------------|------------|---------------|--------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Patient Treatment | 375 | 43.66 | 666 | 53.84 | 1041 | 49.67 |
| Only investigation | 314 | 36.55 | 371 | 29.99 | 685 | 32.68 |
| Second opinion | 170 | 19.79 | 200 | 16.17 | 370 | 17.65 |
| Total | 859 | 100.00 | 1,237 | 100.00 | 2,096 | 100.00 |

Second opinion


17%

Only investigation

33%

Patient Treatment

50%



DISTRIBUTION OF NEW ALL CANCER PATIENTS BY TREATMENT (SOLID TUMOR)

| Primary treatment | Male | | Female | | Total | |
|----------------------------------|------------|---------------|------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Surgery | 114 | 30.40 | 213 | 31.98 | 327 | 31.41 |
| Radiation Therapy | 192 | 51.20 | 374 | 56.16 | 566 | 54.37 |
| Chemotherapy | 27 | 7.20 | 23 | 3.45 | 50 | 4.80 |
| Targeted therapy | 3 | 0.80 | 2 | 0.30 | 5 | 0.48 |
| Hormonal therapy | 0 | 0.00 | 1 | 0.15 | 1 | 0.10 |
| Immunotherapy | 0 | 0.00 | 1 | 0.15 | 1 | 0.10 |
| Intervention Treatment | 5 | 1.33 | 5 | 0.75 | 10 | 0.96 |
| Concurrent chemoradiation | 16 | 4.27 | 5 | 0.75 | 21 | 2.02 |
| Radioactive Iodine Therapy (RAI) | 18 | 4.80 | 42 | 6.31 | 60 | 5.76 |
| Total | 375 | 100.00 | 666 | 100.00 | 1,041 | 100.00 |

Radioactive Iodine Therapy (RAI)

6%

Concurrent chemoradiation

2%

Intervention Treatment

1%

Immunotherapy

0%

Targeted therapy

1%

Chemotherapy


5%

Surgery

31%

Radiation Therapy

54%



PATIENT CATEGORY OF NEW ALL CANCER PATIENTS IN BANGKOK HOSPITAL HEADQUARTER (SOLID TUMOR)

| Type of treatment | Male | | Female | | Total | |
|---------------------------|--------|---------|--------|---------|--------|---------|
| | Number | Percent | Number | Percent | Number | Percent |
| SUR. only | 71 | 8.27 | 84 | 6.79 | 155 | 7.40 |
| RT only | 175 | 20.37 | 365 | 29.51 | 540 | 25.76 |
| CT only | 22 | 2.56 | 18 | 1.46 | 40 | 1.91 |
| Targeted therapy | 3 | 0.35 | 0 | 0.00 | 3 | 0.14 |
| Hormonal therapy | 0 | 0.00 | 1 | 0.08 | 1 | 0.05 |
| Intervention | 5 | 0.58 | 5 | 0.40 | 10 | 0.48 |
| Nuclear medicine | 18 | 2.10 | 42 | 3.40 | 60 | 2.86 |
| Concurrent chemoradiation | 16 | 1.86 | 5 | 0.40 | 21 | 1.00 |
| Immunotherapy | 0 | 0.00 | 1 | 0.08 | 1 | 0.05 |
| SUR.+RT | 8 | 0.93 | 16 | 1.29 | 24 | 1.15 |
| SUR.+CT | 19 | 2.21 | 20 | 1.62 | 39 | 1.86 |
| SUR.+Im | 1 | 0.12 | 1 | 0.08 | 2 | 0.10 |
| SUR.+H | 0 | 0.00 | 20 | 1.62 | 20 | 0.95 |
| SUR.+T | 1 | 0.12 | 3 | 0.24 | 4 | 0.19 |
| SUR.+N | 1 | 0.12 | 15 | 1.21 | 16 | 0.76 |
| SUR.+Concurrent CT-RT | 6 | 0.70 | 3 | 0.24 | 9 | 0.43 |
| RT+Concurrent CT-RT | 3 | 0.35 | 1 | 0.08 | 4 | 0.19 |
| CT+Concurrent CT-RT | 4 | 0.47 | 1 | 0.08 | 5 | 0.24 |
| RT+T | 0 | 0.00 | 2 | 0.16 | 2 | 0.10 |
| RT+CT | 8 | 0.93 | 4 | 0.32 | 12 | 0.57 |
| RT+H | 4 | 0.47 | 2 | 0.16 | 6 | 0.29 |
| RT+Im | 1 | 0.12 | 0 | 0.00 | 1 | 0.05 |
| CT+H | 0 | 0.00 | 2 | 0.16 | 2 | 0.10 |
| CT+T | 0 | 0.00 | 2 | 0.16 | 2 | 0.10 |
| CT+I | 1 | 0.12 | 0 | 0.00 | 1 | 0.05 |
| H+T | 0 | 0.00 | 2 | 0.16 | 2 | 0.10 |

PATIENT CATEGORY OF NEW ALL CANCER PATIENTS IN BANGKOK HOSPITAL HEADQUARTER (SOLID TUMOR)

| Type of treatment | Male | | Female | | Total | |
|--------------------------|------------|---------------|--------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| SUR.+RT+CT | 3 | 0.35 | 11 | 0.89 | 14 | 0.67 |
| SUR.+RT+H | 1 | 0.12 | 14 | 1.13 | 15 | 0.72 |
| SUR.+RT+T | 0 | 0.00 | 1 | 0.08 | 1 | 0.05 |
| SUR.+CT+T | 0 | 0.00 | 1 | 0.08 | 1 | 0.05 |
| SUR.+CT+H | 0 | 0.00 | 1 | 0.08 | 1 | 0.05 |
| SUR.+CT+Concurrent CT-RT | 2 | 0.23 | 1 | 0.08 | 3 | 0.14 |
| SUR.+RT+CT+H | 1 | 0.12 | 13 | 1.05 | 14 | 0.67 |
| SUR.+RT+CT+T | 1 | 0.12 | 3 | 0.24 | 4 | 0.19 |
| SUR.+RT+CT+Im | 0 | 0.00 | 1 | 0.08 | 1 | 0.05 |
| SUR.+CT+T+H | 0 | 0.00 | 2 | 0.16 | 2 | 0.10 |
| SUR.+CT+T+I | 0 | 0.00 | 1 | 0.08 | 1 | 0.05 |
| SUR.+RT+CT+H+T | 0 | 0.00 | 2 | 0.16 | 2 | 0.10 |
| Investigation | 314 | 36.55 | 371 | 29.99 | 685 | 32.68 |
| 2 nd Opinion | 166 | 19.32 | 197 | 15.93 | 363 | 17.32 |
| Supportive | 4 | 0.47 | 3 | 0.24 | 7 | 0.33 |
| Total | 859 | 100.00 | 1,237 | 100.00 | 2,096 | 100.00 |

SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy


H (Hormone) = Hormonal therapy

T = Targeted therapy

I = Intervention

Im = Immunotherapy

DISTRIBUTION OF NEW ALL CANCER PATIENTS BY REFERING HOSPITAL (SOLID TUMOR)



BHQ = Consult from Bangkok general hospital

Paolo Group = Paolo memorial hospital Group

BPH = Bangkok Pattaya Hospital

BNH = BNH Hospital

Other (BDMS) = Other Hospital in Bangkok Hospital Network

PYT Group = Payathai hospital Group

Samitivej Group = Samitivej Hospital Group


BPK = Bangkok Phuket Hospital

BHN = Bangkok Huahin Hospital


Out of BDMS = Other Hospital but not Bangkok Hospital Network

DISTRIBUTION OF NEW ALL CANCER PATIENTS BY NATIONALITY (SOLID TUMOR)

TOTAL PATIENTS NATIONALITY



NON-THAI PATIENTS NATIONALITY




DRITRIBUTION OF NEW ALL CANCER PATIENTS BY FOLLOW UP (SOLID TUMOR)

| Follow up status | Male | | Female | | Total | |
|------------------|------------|---------------|--------------|---------------|--------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 829 | 96.51 | 1,208 | 97.66 | 2,037 | 97.19 |
| Death | 30 | 3.49 | 29 | 2.34 | 59 | 2.81 |
| Total | 859 | 100.00 | 1,237 | 100.00 | 2,096 | 100.00 |

Death

3%




Alive
97%

THE TOP 10 LEADING SITE OF NEW THAI CANCER PATIENTS BY GENDER (SOLID TUMOR)

| Code | Primary site | Male | | Female | | Total | |
|----------|-------------------------|--------|---------|--------|---------|--------|---------|
| | | Number | Percent | Number | Percent | Number | Percent |
| C50, D05 | Breast (included DCIS) | 6 | 1.15 | 503 | 49.07 | 509 | 32.88 |
| C33-C34 | Lung | 101 | 19.31 | 94 | 9.17 | 195 | 12.60 |
| C18-C20 | Colorectal | 85 | 16.25 | 68 | 6.63 | 153 | 9.88 |
| C73 | Thyroid gland | 23 | 4.40 | 94 | 9.17 | 117 | 7.56 |
| C61 | Prostate | 92 | 17.59 | 0 | 0.00 | 92 | 5.94 |
| C53 | Cervix | 0 | 0.00 | 86 | 8.39 | 86 | 5.56 |
| C00-C14 | Head & Neck | 54 | 10.33 | 24 | 2.34 | 78 | 5.04 |
| C22-C24 | Liver and Hepatobiliary | 44 | 8.41 | 14 | 1.37 | 58 | 3.75 |
| C54 | Endometrium | 0 | 0.00 | 53 | 5.17 | 53 | 3.42 |
| C25 | Pancreas | 13 | 2.49 | 18 | 1.76 | 31 | 2.00 |


THE TOP 10 LEADING SITE OF NEW THAI CANCER PATIENTS BY GENDER (SOLID TUMOR)

All Gender



THE TOP 10 LEADING SITE OF NEW THAI CANCER PATIENTS IN MALE (SOLID TUMOR)


Male



2020

TOP 10 CANCER OF NEW CANCER IN THAI PATIENTS IN FEMALE (SOLID TUMOR)

FEMALE




2020

THE TOP 10 LEADING SITE OF NEW NON-THAI CANCER PATIENTS BY GENDER (SOLID TUMOR)


| Code | Primary site | Male | | Female | | Total | |
|----------|-------------------------|--------|---------|--------|---------|--------|---------|
| | | Number | Percent | Number | Percent | Number | Percent |
| C50, D05 | Breast (included DCIS) | 1 | 0.30 | 96 | 45.28 | 97 | 17.70 |
| C61 | Prostate | 71 | 21.13 | 0 | 0.00 | 71 | 12.96 |
| C33-C34 | Lung | 49 | 14.58 | 12 | 5.66 | 61 | 11.13 |
| C18-C20 | Colorectal | 43 | 12.80 | 17 | 8.02 | 60 | 10.95 |
| C73 | Thyroid gland | 22 | 6.55 | 18 | 8.49 | 40 | 7.30 |
| C22-C24 | Liver and Hepatobiliary | 25 | 7.44 | 14 | 6.60 | 39 | 7.12 |
| C00-C14 | Head & Neck | 26 | 7.74 | 7 | 3.30 | 33 | 6.02 |
| C43-C44 | Skin | 17 | 5.06 | 3 | 1.42 | 20 | 3.65 |
| C25 | Pancreas | 15 | 4.46 | 3 | 1.42 | 18 | 3.28 |
| C64-C65 | Kidney | 11 | 3.27 | 2 | 0.94 | 13 | 2.37 |

THE TOP 10 LEADING SITE OF NEW NON-THAI CANCER PATIENTS BY GENDER (SOLID TUMOR)

All Gender




2020



THE TOP 10 LEADING SITE OF NEW NON-THAI CANCER PATIENTS IN MALE (SOLID TUMOR)


Male



2020

THE TOP 10 LEADING SITE OF NEW NON-THAI CANCER PATIENTS IN FEMALE (SOLID TUMOR)

FEMALE



2020

BREAST CANCER : PATHOLOGY


| Tumor site | | Number |
|--------------|--------------------------------|------------|
| 50.0 | Nipple | 1 |
| 50.1 | Central portion of breast | 4 |
| 50.2 | Upper-inner quadrant of breast | 12 |
| 50.3 | Lower-inner quadrant of breast | 10 |
| 50.4 | Upper-outer quadrant of breast | 78 |
| 50.5 | Lower-outer quadrant of breast | 15 |
| 50.6 | Axillary tail | 0 |
| 50.8 | Overlapping lesion of breast | 29 |
| 50.9 | Breast, NOS | 457 |
| Total | | 606 |

| Pathology Report | | Number |
|------------------|---|------------|
| 8000/3 | Malignant neoplasm | 170 |
| 8010/3 | Carcinoma, NOS | 4 |
| 8041/3 | Small cell carcinoma, NOS | 1 |
| 8050/2 | Papillary carcinoma in situ | 1 |
| 8050/3 | Papillary carcinoma, NOS | 1 |
| 8140/3 | Adenocarcinoma, NOS | 3 |
| 8480/3 | Mucinous carcinoma | 3 |
| 8481/3 | Signet ring cell adenocarcinoma | 1 |
| 8500/2 | Ductal carcinoma in situ | 48 |
| 8503/2 | Ductal carcinoma in situ, papillary | 1 |
| 8500/3 | Infiltrating ductal carcinoma | 359 |
| 8520/3 | Invasive lobular carcinoma | 7 |
| 8522/3 | Infiltrating duct and lobular carcinoma | 1 |
| 8801/3 | Spindle cell sarcoma | 1 |
| 9020/3 | Malignant phyllodes tumor | 4 |
| 9120/3 | Angiosarcoma | 1 |
| Total | | 606 |


DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY AGE GROUP

| Age | Male | | Female | | Total | |
|--------------|----------|---------------|------------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 | 1 | 0.17 | 1 | 0.17 |
| 25 - 29 | 0 | 0.00 | 7 | 1.17 | 7 | 1.16 |
| 30 - 34 | 0 | 0.00 | 27 | 4.51 | 27 | 4.46 |
| 35 - 39 | 0 | 0.00 | 48 | 8.01 | 48 | 7.92 |
| 40 - 44 | 0 | 0.00 | 87 | 14.52 | 87 | 14.36 |
| 45 - 49 | 1 | 14.29 | 91 | 15.19 | 92 | 15.18 |
| 50 - 54 | 0 | 0.00 | 107 | 17.86 | 107 | 17.66 |
| 55 - 59 | 2 | 28.57 | 87 | 14.52 | 89 | 14.69 |
| 60 - 64 | 1 | 14.29 | 53 | 8.85 | 54 | 8.91 |
| 65 - 69 | 2 | 28.57 | 39 | 6.51 | 41 | 6.77 |
| 70 - 74 | 0 | 0.00 | 24 | 4.01 | 24 | 3.96 |
| 75 - 79 | 0 | 0.00 | 17 | 2.84 | 17 | 2.81 |
| 80 - 84 | 1 | 14.29 | 3 | 0.50 | 4 | 0.66 |
| 85 - 89 | 0 | 0.00 | 4 | 0.67 | 4 | 0.66 |
| 90 - 94 | 0 | 0.00 | 3 | 0.50 | 3 | 0.50 |
| 95 + | 0 | 0.00 | 1 | 0.17 | 1 | 0.17 |
| Total | 7 | 100.00 | 599 | 100.00 | 606 | 100.00 |

■ Male ■ Female




DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Breast cancer from other Hospital but no documentation of diagnosis

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Stage 0 = Carcinoma in situ

Unspecified stage = Incomplete staging due to insufficient patient information

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

PRIMARY TREATMENT

Hormonal therapy

0%

Targeted therapy

1%

Chemotherapy


1%

Surgery

35%

Radiation therapy

63%



ALL TREATMENT

| Type of treatment | Male | | Female | | Total | |
|-------------------|----------|---------------|------------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| SUR. only | 1 | 25.00 | 38 | 11.52 | 39 | 11.68 |
| RT only | 2 | 50.00 | 203 | 61.52 | 205 | 61.38 |
| Hormonal therapy | 0 | 0.00 | 1 | 0.30 | 1 | 0.30 |
| SUR.+RT | 0 | 0.00 | 12 | 3.64 | 12 | 3.59 |
| SUR.+CT | 0 | 0.00 | 5 | 1.52 | 5 | 1.50 |
| SUR.+H | 0 | 0.00 | 20 | 6.06 | 20 | 5.99 |
| SUR.+T | 0 | 0.00 | 1 | 0.30 | 1 | 0.30 |
| RT+T | 0 | 0.00 | 1 | 0.30 | 1 | 0.30 |
| RT+CT | 0 | 0.00 | 2 | 0.61 | 2 | 0.60 |
| RT+H | 0 | 0.00 | 2 | 0.61 | 2 | 0.60 |
| CT+H | 0 | 0.00 | 2 | 0.61 | 2 | 0.60 |
| CT+T | 0 | 0.00 | 1 | 0.30 | 1 | 0.30 |
| H+T | 0 | 0.00 | 2 | 0.61 | 2 | 0.60 |
| SUR.+RT+CT | 0 | 0.00 | 4 | 1.21 | 4 | 1.20 |
| SUR.+RT+H | 0 | 0.00 | 14 | 4.24 | 14 | 4.19 |
| SUR.+CT+H | 0 | 0.00 | 1 | 0.30 | 1 | 0.30 |
| SUR.+CT+T | 0 | 0.00 | 1 | 0.30 | 1 | 0.30 |
| SUR.+RT+CT+H | 1 | 25.00 | 13 | 3.94 | 14 | 4.19 |
| SUR.+RT+CT+T | 0 | 0.00 | 3 | 0.91 | 3 | 0.90 |
| SUR.+CT+T+H | 0 | 0.00 | 2 | 0.61 | 2 | 0.60 |
| SUR.+RT+CT+T+H | 0 | 0.00 | 2 | 0.61 | 2 | 0.60 |
| Total | 4 | 100.00 | 330 | 100.00 | 334 | 100.00 |

SUR. = Surgery

RT = External radiation therapy


CT = Chemotherapy

H (Hormone) = Hormonal therapy

T = Targeted therapy

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY FOLLOW UP STATUS
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Follow up status | Male | | Female | | Total | |
|------------------|----------|---------------|------------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 4 | 100.00 | 330 | 100.00 | 334 | 100.00 |
| Death | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 4 | 100.00 | 330 | 100.00 | 334 | 100.00 |




LUNG CANCER : PATHOLOGY

| Tumor site | | Number |
|--------------|-------------------|------------|
| 34.0 | Main bronchus | 1 |
| 34.1 | Upper lobe, lung | 83 |
| 34.2 | Middle lobe, lung | 8 |
| 34.3 | Lower lobe, lung | 49 |
| 34.9 | Lung, NOS | 115 |
| Total | | 256 |


| Pathology Report | | Number |
|------------------|--|------------|
| M8000/3 | Malignant neoplasm | 69 |
| M8010/3 | Carcinoma, NOS | 5 |
| M8013/3 | Large cell neuroendocrine carcinoma | 1 |
| M8041/3 | Small cell carcinoma, NOS | 10 |
| M8046/3 | Non small cell carcinoma | 37 |
| M8070/3 | Squamous cell carcinoma, NOS | 12 |
| M8071/3 | Squamous cell carcinoma, keratinizing, NOS | 2 |
| M8140/3 | Adenocarcinoma, NOS | 104 |
| M8240/3 | Carcinoid tumour, NOS | 1 |
| M8246/3 | Neuroendocrine carcinoma | 1 |
| M8480/3 | Mucous adenocarcinoma | 4 |
| M8481/3 | Mucin-producing adenocarcinoma | 1 |
| M8550/3 | Acinar adenocarcinoma | 9 |
| Total | | 256 |

DISTRIBUTION OF NEW LUNG CANCER PATIENTS BY AGE GROUP AND GENDER

| Age | Male | | Female | | Total | |
|--------------|------------|---------------|------------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 30 - 34 | 3 | 2.00 | 2 | 1.89 | 5 | 1.95 |
| 35 - 39 | 2 | 1.33 | 3 | 2.83 | 5 | 1.95 |
| 40 - 44 | 2 | 1.33 | 3 | 2.83 | 5 | 1.95 |
| 45 - 49 | 8 | 5.33 | 6 | 5.66 | 14 | 5.47 |
| 50 - 54 | 17 | 11.33 | 10 | 9.43 | 27 | 10.55 |
| 55 - 59 | 23 | 15.33 | 18 | 16.98 | 41 | 16.02 |
| 60 - 64 | 14 | 9.33 | 23 | 21.70 | 37 | 14.45 |
| 65 - 69 | 30 | 20.00 | 12 | 11.32 | 42 | 16.41 |
| 70 - 74 | 25 | 16.67 | 9 | 8.49 | 34 | 13.28 |
| 75 - 79 | 14 | 9.33 | 11 | 10.38 | 25 | 9.77 |
| 80 - 84 | 6 | 4.00 | 4 | 3.77 | 10 | 3.91 |
| 85 - 89 | 5 | 3.33 | 4 | 3.77 | 9 | 3.52 |
| 90 - 94 | 1 | 0.67 | 1 | 0.94 | 2 | 0.78 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 150 | 100.00 | 106 | 100.00 | 256 | 100.00 |




DISTRIBUTION OF NEW LUNG CANCER PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Lung cancer from other Hospital but no documentation of diagnosis

DISTRIBUTION OF NEW LUNG CANCER PATIENTS BY STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

DISTRIBUTION OF NEW LUNG CANCER PATIENTS BY TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

PRIMARY TREATMENT

Targeted therapy

2%

Concurrent chemoradiation

3%

Chemotherapy


7%

Radiation therapy

56%

Surgery

32%



ALL TREATMENT

| Type of treatment | Male | | Female | | Total | |
|--------------------------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| SUR. only | 12 | 19.05 | 8 | 22.22 | 20 | 20.20 |
| RT only | 33 | 52.38 | 18 | 50.00 | 51 | 51.52 |
| CT only | 4 | 6.35 | 0 | 0.00 | 4 | 4.04 |
| Targeted therapy | 2 | 3.17 | 2 | 5.56 | 4 | 4.04 |
| Concurrent chemoradiation | 3 | 4.76 | 0 | 0.00 | 3 | 3.03 |
| SUR.+CT | 2 | 3.17 | 3 | 8.33 | 5 | 5.05 |
| SUR.+T | 1 | 1.59 | 0 | 0.00 | 1 | 1.01 |
| SUR.+Concurrent chemoradiation | 1 | 1.59 | 0 | 0.00 | 1 | 1.01 |
| RT+CT | 3 | 4.76 | 0 | 0.00 | 3 | 3.03 |
| CT+T | 0 | 0.00 | 1 | 2.78 | 1 | 1.01 |
| RT+T | 0 | 0.00 | 1 | 2.78 | 1 | 1.01 |
| SUR.+RT+CT | 1 | 1.59 | 2 | 5.56 | 3 | 3.03 |
| SUR.+RT+T | 0 | 0.00 | 1 | 2.78 | 1 | 1.01 |
| SUR.+RT+CT+T | 1 | 1.59 | 0 | 0.00 | 1 | 1.01 |
| Total | 63 | 100.00 | 36 | 100.00 | 99 | 100.00 |

SUR. = Surgery


RT = External radiation therapy

CT = Chemotherapy

T = Targeted therapy

DISTRIBUTION OF NEW LUNG CANCER PATIENTS BY FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Follow up status | Male | | Female | | Total | |
|------------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 55 | 87.30 | 36 | 100.00 | 91 | 91.92 |
| Death | 8 | 12.70 | 0 | 0.00 | 8 | 8.08 |
| Total | 63 | 100.00 | 36 | 100.00 | 99 | 100.00 |




COLORECTAL CANCER : PATHOLOGY

| Tumor site | | Number |
|--------------|--------------------------|------------|
| C18.0 | Cecum colon | 7 |
| C18.1 | Appendix | 1 |
| C18.2 | Ascending colon | 13 |
| C18.3 | Hepatic flexure of colon | 1 |
| C18.4 | Transverse colon | 7 |
| C18.5 | Splenic flexure of colon | 5 |
| C18.6 | Descending colon | 8 |
| C18.7 | Sigmoid colon | 29 |
| C18.8 | Overlapping lesion colon | 1 |
| C18.9 | Colon, NOS | 30 |
| C19.9 | Rectosigmoid colon | 23 |
| C20.9 | Rectum | 88 |
| Total | | 213 |

| Pathology Report | | Number |
|------------------|---------------------------------|------------|
| M8000/3 | Malignant neoplasm | 47 |
| M8010/3 | Carcinoma, NOS | 2 |
| M8140/3 | Adenocarcinoma | 154 |
| M8246/3 | Neuroendocrine carcinoma, NOS | 1 |
| M8480/3 | Mucinous adenocarcinoma | 6 |
| M8481/3 | Mucin-producing adenocarcinoma | 2 |
| M8490/3 | Signet ring cell adenocarcinoma | 1 |
| Total | | 213 |

DISTRIBUTION OF NEW COLORECTAL CANCER PATIENTS BY AGE GROUP AND GENDER

| Age | Male | | Female | | Total | |
|--------------|------------|---------------|-----------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 30 - 34 | 2 | 1.56 | 4 | 4.71 | 6 | 2.82 |
| 35 - 39 | 7 | 5.47 | 4 | 4.71 | 11 | 5.16 |
| 40 - 44 | 8 | 6.25 | 2 | 2.35 | 10 | 4.69 |
| 45 - 49 | 7 | 5.47 | 8 | 9.41 | 15 | 7.04 |
| 50 - 54 | 10 | 7.81 | 10 | 11.76 | 20 | 9.39 |
| 55 - 59 | 16 | 12.50 | 10 | 11.76 | 26 | 12.21 |
| 60 - 64 | 22 | 17.19 | 14 | 16.47 | 36 | 16.90 |
| 65 - 69 | 24 | 18.75 | 8 | 9.41 | 32 | 15.02 |
| 70 - 74 | 18 | 14.06 | 8 | 9.41 | 26 | 12.21 |
| 75 - 79 | 8 | 6.25 | 6 | 7.06 | 14 | 6.57 |
| 80 - 84 | 2 | 1.56 | 3 | 3.53 | 5 | 2.35 |
| 85 - 89 | 2 | 1.56 | 2 | 2.35 | 4 | 1.88 |
| 90 - 94 | 1 | 0.78 | 4 | 4.71 | 5 | 2.35 |
| 95 + | 1 | 0.78 | 2 | 2.35 | 3 | 1.41 |
| Total | 128 | 100.00 | 85 | 100.00 | 213 | 100.00 |



DISTRIBUTION OF NEW COLORECTAL CANCER PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Physician Examination

6%

X-ray, CT, Ultrasound


2%

Pathology of metastasis organ


3%

Pathology of primary organ

89%



DISTRIBUTION OF NEW COLORECTAL CANCER PATIENTS BY STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



DISTRIBUTION OF NEW COLORECTAL CANCER PATIENTS BY TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

PRIMARY TREATMENT

Concurrent chemoradiation

5%

Chemotherapy


15%

Radiation therapy

40%

Surgery

40%



ALL TREATMENT

| Type of treatment | Male | | Female | | Total | |
|--------------------------|-----------|---------------|-----------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| SUR. only | 13 | 19.40 | 7 | 20.59 | 20 | 19.80 |
| RT only | 25 | 37.31 | 13 | 38.24 | 38 | 37.62 |
| CT only | 7 | 10.45 | 6 | 17.65 | 13 | 12.87 |
| Concurrent CT-RT | 4 | 5.97 | 1 | 2.94 | 5 | 4.95 |
| SUR.+CT | 9 | 13.43 | 7 | 20.59 | 16 | 15.84 |
| SUR.+RT | 1 | 1.49 | 0 | 0.00 | 1 | 0.99 |
| SUR.+Concurrent CT-RT | 3 | 4.48 | 0 | 0.00 | 3 | 2.97 |
| RT+CT | 1 | 1.49 | 0 | 0.00 | 1 | 0.99 |
| RT+Concurrent CT-RT | 1 | 1.49 | 0 | 0.00 | 1 | 0.99 |
| CT+Concurrent CT-RT | 1 | 1.49 | 0 | 0.00 | 1 | 0.99 |
| CT+I | 1 | 1.49 | 0 | 0.00 | 1 | 0.99 |
| SUR.+CT+Concurrent CT-RT | 1 | 1.49 | 0 | 0.00 | 1 | 0.99 |
| Total | 67 | 100.00 | 34 | 100.00 | 101 | 100.00 |

SUR. = Surgery

RT = External radiation therapy

CT = Chemotherapy


T = Targeted therapy

DISTRIBUTION OF NEW COLORECTAL CANCER PATIENTS BY FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Follow up status | Male | | Female | | Total | |
|------------------|-----------|---------------|-----------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 65 | 97.01 | 30 | 88.24 | 95 | 94.06 |
| Death | 2 | 2.99 | 4 | 11.76 | 6 | 5.94 |
| Total | 67 | 100.00 | 34 | 100.00 | 101 | 100.00 |

Death

6%



Alive
94%

PROSTATE CANCER : PATHOLOGY


| Tumor site | | Number |
|------------|----------|--------|
| C61.9 | Prostate | 163 |
| Total | | 163 |

| Pathology Report | | Number |
|------------------|-----------------------|--------|
| M8000/3 | Malignant neoplasm | 55 |
| M8010/3 | Carcinoma, NOS | 1 |
| M8140/3 | Adenocarcinoma, NOS | 58 |
| M8550/3 | Acinar adenocarcinoma | 49 |
| Total | | 163 |

DISTRIBUTION OF NEW PROSTATE CANCER PATIENTS BY AGE GROUP

| Age | Male | |
|--------------|------------|---------------|
| | Number | Percent |
| 15 - 19 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 |
| 30 - 34 | 0 | 0.00 |
| 35 - 39 | 0 | 0.00 |
| 40 - 44 | 0 | 0.00 |
| 45 - 49 | 0 | 0.00 |
| 50 - 54 | 11 | 6.75 |
| 55 - 59 | 9 | 5.52 |
| 60 - 64 | 28 | 17.18 |
| 65 - 69 | 38 | 23.31 |
| 70 - 74 | 37 | 22.70 |
| 75 - 79 | 21 | 12.88 |
| 80 - 84 | 13 | 7.98 |
| 85 - 89 | 6 | 3.68 |
| 90 - 94 | 0 | 0.00 |
| 95 + | 0 | 0.00 |
| Total | 163 | 100.00 |


■ Male




DISTRIBUTION OF NEW PROSTATE CANCER PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

Physician Examination
9%

Pathology of primary organ
91%




DISTRIBUTION OF NEW PROSTATE CANCER PATIENTS BY STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

DISTRIBUTION OF PROSTATE CANCER PATIENTS BY TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

PRIMARY TREATMENT



ALL TREATMENT

| Type of treatment | Male | |
|--|-----------|---------------|
| | Number | Percent |
| Surgery. only | 3 | 5.66 |
| Radiation therapy only | 43 | 81.13 |
| Surgery + Radiation therapy | 2 | 3.77 |
| Radiation therapy + Hormonal therapy | 4 | 7.55 |
| Surgery + Radiation therapy + Hormonal therapy | 1 | 1.89 |
| Total | 53 | 100.00 |

SUR. = Surgery

RT = External radiation therapy


CT = Chemotherapy

T = Targeted therapy

I = Intervention

DISTRIBUTION OF NEW PROSTATE CANCER PATIENTS BY FOLLOW UP STATUS
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Follow up status | Male | |
|------------------|-----------|---------------|
| | Number | Percent |
| Alive | 53 | 100.00 |
| Death | 0 | 0.00 |
| Total | 53 | 100.00 |



THYROID CANCER : PATHOLOGY


| Tumor site | | Number |
|--------------|---------------|------------|
| C73.9 | Thyroid gland | 157 |
| Total | | 157 |

| Pathology Report | | Number |
|------------------|--|------------|
| M8000/3 | Malignant neoplasm | 4 |
| M8021/3 | Anaplastic carcinoma | 1 |
| M8260/3 | Papillary carcinoma of thyroid | 82 |
| M8290/3 | Hurthle cell carcinoma | 4 |
| M8330/3 | Follicular carcinoma, NOS | 9 |
| M8335/3 | Follicular carcinoma, minimally invasive | 1 |
| M8340/3 | Papillary carcinoma follicular variant | 22 |
| M8341/3 | Papillary microcarcinoma | 24 |
| M8344/3 | Papillary carcinoma, tall cell | 9 |
| M8345/3 | Medullary carcinoma of thyroid | 1 |
| Total | | 157 |


DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY AGE GROUP AND GENDER

| Age | Male | | Female | | Total | |
|--------------|-----------|---------------|------------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 1 | 2.22 | 2 | 1.79 | 3 | 1.91 |
| 20 - 24 | 1 | 2.22 | 1 | 0.89 | 2 | 1.27 |
| 25 - 29 | 2 | 4.44 | 9 | 8.04 | 11 | 7.01 |
| 30 - 34 | 2 | 4.44 | 12 | 10.71 | 14 | 8.92 |
| 35 - 39 | 4 | 8.89 | 8 | 7.14 | 12 | 7.64 |
| 40 - 44 | 13 | 28.89 | 15 | 13.39 | 28 | 17.83 |
| 45 - 49 | 5 | 11.11 | 14 | 12.50 | 19 | 12.10 |
| 50 - 54 | 5 | 11.11 | 18 | 16.07 | 23 | 14.65 |
| 55 - 59 | 4 | 8.89 | 12 | 10.71 | 16 | 10.19 |
| 60 - 64 | 4 | 8.89 | 8 | 7.14 | 12 | 7.64 |
| 65 - 69 | 3 | 6.67 | 6 | 5.36 | 9 | 5.73 |
| 70 - 74 | 1 | 2.22 | 4 | 3.57 | 5 | 3.18 |
| 75 - 79 | 0 | 0.00 | 3 | 2.68 | 3 | 1.91 |
| 80 - 84 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 85 - 89 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 45 | 100.00 | 112 | 100.00 | 157 | 100.00 |

■ Male ■ Female




DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Physician Examination = Previously diagnosed as Head and Neck cancer from other Hospital but no document of Pathology


DISTRIBUTION OF THYROID CANCER PATIENTS BY STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)



Unspecified stage = Incomplete staging due to insufficient patient information

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

PRIMARY TREATMENT




ALL TREATMENT

| Type of treatment | Male | | Female | | Total | |
|--|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Surgery | 5 | 20.83 | 15 | 20.83 | 20 | 20.83 |
| Radioactive Iodine Therapy (RAI) | 18 | 75.00 | 42 | 58.33 | 60 | 62.50 |
| Surgery + Radioactive Iodine Therapy (RAI) | 1 | 4.17 | 15 | 20.83 | 16 | 16.67 |
| Total | 24 | 100.00 | 72 | 100.00 | 96 | 100.00 |

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Follow up status | Male | | Female | | Total | |
|------------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 24 | 100.00 | 72 | 100.00 | 96 | 100.00 |
| Death | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 24 | 100.00 | 72 | 100.00 | 96 | 100.00 |




HEMATOLOGIC MALIGNANCIES 2021

DISTRIBUTION OF HEMATOLOGIC MALIGNANCIES


| Code | Disease | Male | | Female | | Total | |
|--------------|--|-----------|---------------|-----------|---------------|------------|---------------|
| | | Number | Percent | Number | Percent | Number | Percent |
| C81 | Hodgkin's disease | 12 | 14.29 | 4 | 6.45 | 16 | 10.96 |
| C82 | Follicular NHL | 0 | 0.00 | 5 | 8.06 | 5 | 3.42 |
| C83 | Diffuse large B-cell lymphoma | 31 | 36.90 | 28 | 45.16 | 59 | 40.41 |
| C84 | Peripheral and cutaneous T-cell lymphoma | 1 | 1.19 | 1 | 1.61 | 2 | 1.37 |
| C85 | Other and unspecified type of NHL | 7 | 8.33 | 4 | 6.45 | 11 | 7.53 |
| C88 | Waldenstrom macroglobulinemia | 2 | 2.38 | 0 | 0.00 | 2 | 1.37 |
| C90 | Multiple myeloma | 10 | 11.90 | 4 | 6.45 | 14 | 9.59 |
| C91 | Lymphoid leukemia | 4 | 4.76 | 5 | 8.06 | 9 | 6.16 |
| C92 | Myeloid leukemia | 9 | 10.71 | 9 | 14.52 | 18 | 12.33 |
| C94 | AML, M6 | 1 | 1.19 | 0 | 0.00 | 1 | 0.68 |
| D46 | Myelodysplastic syndrome, NOS | 7 | 8.33 | 2 | 3.23 | 9 | 6.16 |
| Total | | 84 | 100.00 | 62 | 100.00 | 146 | 100.00 |

All Gender



DISTRIBUTION OF NEW ALL HEMATOLOGIC MALIGNANCIES BY AGE GROUP AND GENDER

| Age | Male | | Female | | Total | |
|--------------|-----------|---------------|-----------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 0 | 0.00 | 1 | 1.61 | 1 | 0.68 |
| 20 - 24 | 0 | 0.00 | 2 | 3.23 | 2 | 1.37 |
| 25 - 29 | 4 | 4.76 | 10 | 16.13 | 14 | 9.59 |
| 30 - 34 | 4 | 4.76 | 4 | 6.45 | 8 | 5.48 |
| 35 - 39 | 2 | 2.38 | 4 | 6.45 | 6 | 4.11 |
| 40 - 44 | 11 | 13.10 | 2 | 3.23 | 13 | 8.90 |
| 45 - 49 | 4 | 4.76 | 9 | 14.52 | 13 | 8.90 |
| 50 - 54 | 6 | 7.14 | 4 | 6.45 | 10 | 6.85 |
| 55 - 59 | 6 | 7.14 | 5 | 8.06 | 11 | 7.53 |
| 60 - 64 | 10 | 11.90 | 7 | 11.29 | 17 | 11.64 |
| 65 - 69 | 13 | 15.48 | 6 | 9.68 | 19 | 13.01 |
| 70 - 74 | 7 | 8.33 | 4 | 6.45 | 11 | 7.53 |
| 75 - 79 | 11 | 13.10 | 1 | 1.61 | 12 | 8.22 |
| 80 - 84 | 3 | 3.57 | 1 | 1.61 | 4 | 2.74 |
| 85 - 89 | 3 | 3.57 | 2 | 3.23 | 5 | 3.42 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 84 | 100.00 | 62 | 100.00 | 146 | 100.00 |




DISTRIBUTION OF NEW ALL HEMATOLOGIC MALIGNANCIES PATIENTS BY NATIONALITY

| Patient Nationality | Male | | Female | | Total | |
|---------------------|-----------|---------------|-----------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Thai | 53 | 63.10 | 50 | 80.65 | 103 | 70.55 |
| Non-Thai | 31 | 36.90 | 12 | 19.35 | 43 | 29.45 |
| Total | 84 | 100.00 | 62 | 100.00 | 146 | 100.00 |

Non-Thai

29%




Thai
71%

DISTRIBUTION OF NEW ALL HEMATOLOGIC MALIGNANCIES PATIENTS BY FOLLOW UP STATUS

| Follow up status | Male | | Female | | Total | |
|------------------|-----------|---------------|-----------|---------------|------------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 78 | 92.86 | 57 | 91.94 | 135 | 92.47 |
| Death | 6 | 7.14 | 5 | 8.06 | 11 | 7.53 |
| Total | 84 | 100.00 | 62 | 100.00 | 146 | 100.00 |

Death

8%




Alive
92%

LYMPHOMA


DISTRIBUTION OF NEW LYMPHOMA PATIENTS BY AGE GROUP AND GENDER

| Age | Male | | Female | | Total | |
|--------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 | 2 | 4.76 | 2 | 2.11 |
| 25 - 29 | 4 | 7.55 | 10 | 23.81 | 14 | 14.74 |
| 30 - 34 | 3 | 5.66 | 2 | 4.76 | 5 | 5.26 |
| 35 - 39 | 2 | 3.77 | 3 | 7.14 | 5 | 5.26 |
| 40 - 44 | 8 | 15.09 | 2 | 4.76 | 10 | 10.53 |
| 45 - 49 | 0 | 0.00 | 6 | 14.29 | 6 | 6.32 |
| 50 - 54 | 3 | 5.66 | 1 | 2.38 | 4 | 4.21 |
| 55 - 59 | 6 | 11.32 | 2 | 4.76 | 8 | 8.42 |
| 60 - 64 | 5 | 9.43 | 4 | 9.52 | 9 | 9.47 |
| 65 - 69 | 6 | 11.32 | 4 | 9.52 | 10 | 10.53 |
| 70 - 74 | 3 | 5.66 | 3 | 7.14 | 6 | 6.32 |
| 75 - 79 | 9 | 16.98 | 0 | 0.00 | 9 | 9.47 |
| 80 - 84 | 2 | 3.77 | 1 | 2.38 | 3 | 3.16 |
| 85 - 89 | 2 | 3.77 | 2 | 4.76 | 4 | 4.21 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 53 | 100.00 | 42 | 100.00 | 95 | 100.00 |




DISTRIBUTION OF NEW LYMPHOMA PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Method of diagnosis | Male | | Female | | Total | |
|----------------------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Pathology of primary organ | 26 | 100.00 | 18 | 100.00 | 44 | 100.00 |
| Total | 26 | 100.00 | 18 | 100.00 | 44 | 100.00 |



DISTRIBUTION OF NEW LYMPHOMA PATIENTS BY STAGING (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)




Unspecified stage = Incomplete staging due to insufficient patient information

DISTRIBUTION OF NEW LYMPHOMA PATIENTS BY TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Primary treatment | Male | | Female | | Total | |
|----------------------------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Radiation therapy | 10 | 38.46 | 10 | 55.56 | 20 | 45.45 |
| Chemotherapy | 14 | 53.85 | 8 | 44.44 | 22 | 50.00 |
| Radiation therapy + Chemotherapy | 2 | 7.69 | 0 | 0.00 | 2 | 4.55 |
| Total | 26 | 100.00 | 18 | 100.00 | 44 | 100.00 |

Radiation therapy +
Chemotherapy

5%



Chemotherapy


50%

Radiation therapy

45%

DISTRIBUTION OF NEW LYMPHOMA PATIENTS BY FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


| Follow up status | Male | | Female | | Total | |
|------------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 26 | 100.00 | 17 | 94.44 | 43 | 97.73 |
| Death | 0 | 0.00 | 1 | 5.56 | 1 | 2.27 |
| Total | 26 | 100.00 | 18 | 100.00 | 44 | 100.00 |



MULTIPLE MYELOMA


DISTRIBUTION OF NEW MULTIPLE MYELOMA PATIENTS BY AGE GROUP AND GENDER

| Age | Male | | Female | | Total | |
|--------------|-----------|---------------|----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 30 - 34 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 35 - 39 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 40 - 44 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 45 - 49 | 1 | 10.00 | 1 | 25.00 | 2 | 14.29 |
| 50 - 54 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 55 - 59 | 1 | 10.00 | 1 | 25.00 | 2 | 14.29 |
| 60 - 64 | 3 | 30.00 | 1 | 25.00 | 4 | 28.57 |
| 65 - 69 | 1 | 10.00 | 0 | 0.00 | 1 | 7.14 |
| 70 - 74 | 1 | 10.00 | 0 | 0.00 | 1 | 7.14 |
| 75 - 79 | 1 | 10.00 | 1 | 25.00 | 2 | 14.29 |
| 80 - 84 | 1 | 10.00 | 0 | 0.00 | 1 | 7.14 |
| 85 - 89 | 1 | 10.00 | 0 | 0.00 | 1 | 7.14 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 10 | 100.00 | 4 | 100.00 | 14 | 100.00 |



DISTRIBUTION OF NEW MULTIPLE MYELOMA PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Method of diagnosis | Male | | Female | | Total | |
|----------------------------|----------|---------------|----------|---------------|----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Pathology of primary organ | 2 | 100.00 | 2 | 100.00 | 4 | 100.00 |
| Total | 2 | 100.00 | 2 | 100.00 | 4 | 100.00 |




DISTRIBUTION OF NEW MULTIPLE MYELOMA PATIENTS BY TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Primary treatment | Male | | Female | | Total | |
|---------------------------------|----------|---------------|----------|---------------|----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Radiation therapy | 0 | 0.00 | 2 | 100.00 | 2 | 50.00 |
| Chemotherapy + Targeted Therapy | 1 | 50.00 | 0 | 0.00 | 1 | 25.00 |
| Immunotherapy | 1 | 50.00 | 0 | 0.00 | 1 | 25.00 |
| Total | 2 | 100.00 | 2 | 100.00 | 4 | 100.00 |

Immunotherapy

25%



Radiation therapy


50%

Chemotherapy +
Targeted Therapy

25%

DISTRIBUTION OF NEW MULTIPLE MYELOMA PATIENTS BY FOLLOW UP STATUS
(TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)


| Follow up status | Male | | Female | | Total | |
|------------------|----------|---------------|----------|---------------|----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 2 | 100.00 | 2 | 100.00 | 4 | 100.00 |
| Death | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 2 | 100.00 | 2 | 100.00 | 4 | 100.00 |



LEUKEMIA


DISTRIBUTION OF NEW LEUKEMIA PATIENTS BY AGE GROUP AND GENDER

| Age | Male | | Female | | Total | |
|--------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| 15 - 19 | 0 | 0.00 | 1 | 7.14 | 1 | 3.57 |
| 20 - 24 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 25 - 29 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 30 - 34 | 1 | 7.14 | 2 | 14.29 | 3 | 10.71 |
| 35 - 39 | 0 | 0.00 | 1 | 7.14 | 1 | 3.57 |
| 40 - 44 | 3 | 21.43 | 0 | 0.00 | 3 | 10.71 |
| 45 - 49 | 2 | 14.29 | 2 | 14.29 | 4 | 14.29 |
| 50 - 54 | 1 | 7.14 | 1 | 7.14 | 2 | 7.14 |
| 55 - 59 | 0 | 0.00 | 2 | 14.29 | 2 | 7.14 |
| 60 - 64 | 2 | 14.29 | 2 | 14.29 | 4 | 14.29 |
| 65 - 69 | 3 | 21.43 | 2 | 14.29 | 5 | 17.86 |
| 70 - 74 | 2 | 14.29 | 1 | 7.14 | 3 | 10.71 |
| 75 - 79 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 80 - 84 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 85 - 89 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 90 - 94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| 95 + | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 14 | 100.00 | 14 | 100.00 | 28 | 100.00 |



DISTRIBUTION OF NEW LEUKEMIA PATIENTS BY TYPE OF DIAGNOSIS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Method of diagnosis | Male | | Female | | Total | |
|----------------------------|----------|---------------|----------|---------------|----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Cytology | 1 | 16.67 | 0 | 0.00 | 1 | 11.11 |
| Pathology of primary organ | 5 | 83.33 | 3 | 100.00 | 8 | 88.89 |
| Total | 6 | 100.00 | 3 | 100.00 | 9 | 100.00 |



DISTRIBUTION OF NEW LEUKEMIA PATIENTS BY TYPE OF TREATMENT (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Primary treatment | Male | | Female | | Total | |
|--|----------|---------------|----------|---------------|----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Chemotherapy | 3 | 50.00 | 2 | 66.67 | 5 | 55.56 |
| Chemotherapy + Stem cell Transplantation | 2 | 33.33 | 1 | 33.33 | 3 | 33.33 |
| Stem cell Transplantation | 1 | 16.67 | 0 | 0.00 | 1 | 11.11 |
| Total | 6 | 100.00 | 3 | 100.00 | 9 | 100.00 |

Stem cell Transplantation


11%

Chemotherapy + Stem cell Transplantation

33%


Chemotherapy

56%



DISTRIBUTION OF NEW LEUKEMIA PATIENTS BY FOLLOW UP STATUS (TREATMENT IN BANGKOK HOSPITAL HEADQUARTER)

| Follow up status | Male | | Female | | Total | |
|------------------|----------|---------------|----------|---------------|----------|---------------|
| | Number | Percent | Number | Percent | Number | Percent |
| Alive | 3 | 50.00 | 3 | 100.00 | 6 | 66.67 |
| Death | 3 | 50.00 | 0 | 0.00 | 3 | 33.33 |
| Total | 6 | 100.00 | 3 | 100.00 | 9 | 100.00 |



AGE DISTRIBUTION IN ALL MALE CANCER NUMBER OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

| Code | Primary site | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90-94 | 95+ | Total | % |
|---------|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|-------|
| C00 | Lip | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C01-C02 | Tongue | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 4 | 3 | 3 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 19 | 2.01 |
| C03 | Gum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C04 | Floor of mouth | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C05 | Palate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C06 | Other part of mouth | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 3 | 0.32 |
| C07 | Parotid gland | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 | 0.53 |
| C08 | Other and unspecified major salivary glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C09 | Tonsil | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 5 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 12 | 1.27 |
| C10 | Oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.21 |
| C11-C14 | Head and Neck | 0 | 0 | 0 | 2 | 6 | 5 | 6 | 3 | 3 | 4 | 3 | 2 | 3 | 0 | 0 | 0 | 0 | 37 | 3.92 |
| C15 | Esophagus | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 2 | 4 | 3 | 2 | 1 | 0 | 0 | 0 | 17 | 1.80 |
| C16 | Stomach | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 14 | 1.48 |
| C17 | Small intestine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C18-C20 | Colon and Rectum | 0 | 0 | 0 | 2 | 7 | 8 | 7 | 10 | 16 | 22 | 24 | 18 | 8 | 2 | 2 | 1 | 1 | 128 | 13.57 |
| C21 | Anus | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 5 | 0.53 |
| C22-C24 | Liver and Hepatobiliary | 1 | 0 | 0 | 0 | 4 | 6 | 2 | 11 | 6 | 8 | 10 | 10 | 6 | 2 | 2 | 1 | 0 | 69 | 7.32 |
| C25 | Pancreas | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 6 | 5 | 8 | 3 | 0 | 0 | 1 | 0 | 0 | 28 | 2.97 |
| C26 | Other and ill-defined digestive organ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C30 | Nasal cavity | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0.64 |
| C31 | Accessory sinuses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.21 |
| C32 | Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 12 | 1.27 |
| C33-C34 | Lung | 0 | 0 | 0 | 3 | 2 | 2 | 8 | 17 | 23 | 14 | 30 | 25 | 14 | 6 | 5 | 1 | 0 | 150 | 15.91 |
| C37 | Thymus | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0.32 |
| C38 | Mediastinum | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0.32 |
| C40-C41 | Bone | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.21 |
| C43-C44 | Skin | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 5 | 2 | 5 | 2 | 3 | 1 | 1 | 0 | 0 | 21 | 2.23 |
| C48 | Retroperitoneum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C49 | Connective tissue | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 11 | 1.17 |
| C50 | Breast | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 0.74 |
| C51 | Vulva | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C52 | Vagina | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C53 | Cervix | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C54 | Corpus uteri | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C55 | Uterus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |

| Code | Primary site | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90-94 | 95+ | Total | % |
|----------------------|---|----------|----------|-----------|-----------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|-----------|-----------|-----------|----------|----------|------------|---------------|
| C56 | Ovary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C57 | Other female genital organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C58 | Placenta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C60 | Penis | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0.32 |
| C61 | Prostate gland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 9 | 28 | 38 | 37 | 21 | 13 | 6 | 0 | 0 | 163 | 17.29 |
| C62 | Testis | 0 | 1 | 3 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0.74 |
| C63 | Other and unspecified male genital organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C64-C65 | Urinary tract | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 4 | 5 | 3 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 22 | 2.33 |
| C66 | Ureter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C67 | Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 1 | 4 | 3 | 4 | 2 | 0 | 0 | 0 | 0 | 21 | 2.23 |
| C68 | Urinary organ unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C69 | Eye and Adnexa | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C70-C71 | Brain | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 16 | 1.70 |
| C72 | Spinal cord and CNS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C73 | Thyroid gland | 1 | 1 | 2 | 2 | 4 | 13 | 5 | 5 | 4 | 4 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 45 | 4.77 |
| C74 | Adrenal gland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C75 | Parathyroid gland | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C76 | Abdomen, NOS | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C79 | Unknown primary site | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 3 | 0 | 3 | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 18 | 1.91 |
| C81 | Hodgkin's disease | 0 | 0 | 3 | 0 | 1 | 4 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 12 | 1.27 |
| C82 | Follicular NHL | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C83 | Diffuse NHL | 0 | 0 | 1 | 3 | 1 | 4 | 0 | 0 | 4 | 4 | 4 | 2 | 6 | 1 | 1 | 0 | 0 | 31 | 3.29 |
| C84 | Peripheral and cutaneous T-cell lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| C85 | Other and unspecified type of NHL | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 7 | 0.74 |
| C88 | Waldenstrom macroglobulinemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 0.21 |
| C90 | Multiple myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 10 | 1.06 |
| C91 | Lymphoid leukemia | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0.42 |
| C92 | Myeloid leukemia | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 9 | 0.95 |
| C94 | AML M6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.11 |
| D46 | Myelodysplastic syndrome | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 7 | 0.74 |
| D05 | Ductal carcinoma in situ of breast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| All ICD Group | | 3 | 3 | 12 | 18 | 36 | 61 | 49 | 97 | 109 | 120 | 169 | 124 | 82 | 33 | 23 | 3 | 1 | 943 | 100.00 |


AGE DISTRIBUTION IN ALL FEMALE CANCER NUMBER OF CASE (INCLUDED HEMATOLOGIC MALIGNANCIES)

| Code | Primary site | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90-94 | 95+ | Total | % |
|---------|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|-------|-------|
| C00 | Lip | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.08 |
| C01-C02 | Tongue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 8 | 0.62 |
| C03 | Gum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0.08 |
| C04 | Floor of mouth | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C05 | Palate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C06 | Other part of mouth | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.08 |
| C07 | Parotid gland | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.15 |
| C08 | Other and unspecified major salivary glands | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.15 |
| C09 | Tonsil | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0.31 |
| C10 | Oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C11-C14 | Head and Neck | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 12 | 0.92 |
| C15 | Esophagus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0.31 |
| C16 | Stomach | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 4 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 11 | 0.85 |
| C17 | Small Intestine | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.15 |
| C18-C20 | Colon and Rectum | 0 | 0 | 0 | 4 | 4 | 2 | 8 | 10 | 10 | 14 | 8 | 8 | 6 | 3 | 2 | 4 | 2 | 85 | 6.54 |
| C21 | Anus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0.15 |
| C22-C24 | Liver and Hepatobiliary | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 4 | 3 | 8 | 2 | 3 | 2 | 1 | 0 | 0 | 28 | 2.16 |
| C25 | Pancreas | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 4 | 4 | 2 | 3 | 0 | 1 | 0 | 0 | 21 | 1.62 |
| C26 | Other and ill-defined digestive organ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C30 | Nasal cavity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.08 |
| C31 | Accessory sinuses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C32 | Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0.08 |
| C33-C34 | Lung | 0 | 0 | 0 | 2 | 3 | 3 | 6 | 10 | 18 | 23 | 12 | 9 | 11 | 4 | 4 | 1 | 0 | 106 | 8.16 |
| C37 | Thymus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C38 | Mediastinum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C40-C41 | Bone | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0.15 |
| C43-C44 | Skin | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 9 | 0.69 |
| C48 | Retroperitoneum | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.08 |
| C49 | Connective tissue | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0.54 |
| C50 | Breast | 0 | 1 | 7 | 24 | 44 | 83 | 83 | 95 | 82 | 48 | 35 | 23 | 14 | 3 | 4 | 2 | 1 | 549 | 42.26 |
| C51 | Vulva | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 0.38 |
| C52 | Vagina | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.15 |
| C53 | Cervix | 0 | 1 | 1 | 10 | 14 | 17 | 8 | 13 | 17 | 5 | 1 | 0 | 3 | 2 | 0 | 1 | 0 | 93 | 7.16 |
| C54 | Corpus uteri | 0 | 1 | 0 | 6 | 2 | 3 | 6 | 8 | 9 | 6 | 13 | 8 | 1 | 1 | 0 | 1 | 0 | 65 | 5.00 |
| C55 | Uterus | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.08 |

| Code | Primary site | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | 85-89 | 90-94 | 95+ | Total | % |
|----------------------|---|----------|----------|-----------|-----------|-----------|------------|------------|------------|------------|------------|------------|-----------|-----------|-----------|-----------|-----------|----------|--------------|---------------|
| C56 | Ovary | 1 | 0 | 0 | 1 | 2 | 2 | 1 | 5 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 18 | 1.39 |
| C57 | Other female genital organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C58 | Placenta | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C60 | Penis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C61 | Prostate gland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C62 | Testis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C63 | Other and unspecified male genital organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C64-C65 | Urinary tract | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 5 | 0.38 |
| C66 | Ureter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C67 | Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 11 | 0.85 |
| C68 | Urinary organ unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C69 | Eye and Adnexa | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.08 |
| C70-C71 | Brain | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 10 | 0.77 |
| C72 | Spinal cord and CNS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C73 | Thyroid gland | 2 | 1 | 9 | 12 | 8 | 15 | 14 | 18 | 12 | 8 | 6 | 4 | 3 | 0 | 0 | 0 | 0 | 112 | 8.62 |
| C74 | Adrenal gland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| C79 | Unknown primary site | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0.31 |
| C81 | Hodgkin's disease | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0.31 |
| C82 | Follicular NHL | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0.38 |
| C83 | Diffuse NHL | 0 | 0 | 6 | 1 | 2 | 2 | 4 | 0 | 2 | 2 | 3 | 3 | 0 | 1 | 2 | 0 | 0 | 28 | 2.16 |
| C84 | Peripheral and cutaneous T-cell lymphoma | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.08 |
| C85 | Other and unspecified type of NHL | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0.31 |
| C90 | Multiple myeloma | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 4 | 0.31 |
| C91 | Lymphoid leukemia | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 | 0.38 |
| C92 | Myeloid leukemia | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0.69 |
| C95 | Leukemia of unspecified cell type | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00 |
| D05 | Ductal carcinoma in situ of breast | 0 | 0 | 0 | 3 | 4 | 4 | 8 | 12 | 5 | 5 | 4 | 1 | 3 | 0 | 0 | 1 | 0 | 50 | 3.85 |
| D46 | Myelodysplastic syndrome | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.15 |
| All ICD Group | | 4 | 7 | 31 | 69 | 96 | 142 | 155 | 191 | 179 | 137 | 108 | 72 | 58 | 20 | 16 | 11 | 3 | 1,299 | 100.00 |



Bangkok Dusit Medical Services



HOSPITAL :



NON HOSPITAL :



2 Soi Soonvijai 7, New Petchburi Rd., Huaykwang, Bangkok 10310 Thailand

Tel: 0 2310 3000, +662 BANGKOK or 1719 (local calls only) Fax: 0 2310 3088, 0 2310 3327

www.wattanosothcancerhospital.com